Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy

Phys Imaging Radiat Oncol. 2023 Aug 16:27:100481. doi: 10.1016/j.phro.2023.100481. eCollection 2023 Jul.

Abstract

Hybrid systems that combine Magnetic Resonance Imaging (MRI) and linear accelerators are available clinically to guide and adapt radiotherapy. Vendor-approved MRI sequences are provided, however alternative sequences may offer advantages. The aim of this study was to develop a systematic approach for non-vendor sequence evaluation, to determine safety, accuracy and overall clinical application of two potential sequences for bladder cancer MRI guided radiotherapy. Non-vendor sequences underwent and passed clinical image qualitative review, phantom quality assurance, and radiotherapy planning assessments. Volunteer workflow tests showed the potential for one sequence to reduce workflow time by 27% compared to the standard vendor sequence.

Keywords: Adaptive radiotherapy; Bladder cancer; MRI guided radiotherapy; MRI sequence evaluation; Non-vendor sequences; Quality assurance.